
1. gene ther. 2016 mar;23(3):313-9. doi: 10.1038/gt.2015.109. epub 2015 dec 24.

prevalence aav1 neutralizing antibodies consequences clinical trial 
of gene transfer advanced heart failure.

greenberg b(1), butler j(2), felker gm(3), ponikowski p(4), voors aa(5), pogoda
jm(6), provost r(6), guerrero j(6), hajjar rj(7), zsebo km(8).

author information: 
(1)sulpizio cardiovascular center, university california, san diego, la jolla,
ca, usa.
(2)stony brook university, stony brook, ny, usa.
(3)duke university school medicine, durham, nc, usa.
(4)wroclaw medical university military hospital, wroclaw, poland.
(5)university groningen, groningen, netherlands.
(6)celladon corporation, san diego, ca, usa.
(7)cardiovascular research center, icahn school medicine mount sinai, new
york, ny, usa.
(8)biovest consulting, llc, santa barbara, ca, usa.

adeno-associated virus serotype 1 (aav1) many advantages gene therapy
vector, presence pre-existing neutralizing antibodies (nabs) an
important limitation. study designed determine: (1) characteristics
of aav nabs human subjects, (2) prevalence aav1 nabs heart failure
patients (3) utility aggressive immunosuppressive therapy reducing nab 
seroconversion animal model. nab titers assessed cohort heart 
failure patients patients screened clinical trial gene therapy
with aav1 carrying sarcoplasmic reticulum calcium atpase gene (aav1/serca2a).
aav1 nabs found 59.5% 1552 heart failure patients. nab prevalence
increased age (p=0.001) varied geographically. pattern nab titers
suggested exposure aav2, aav1 nab seropositivity due to
crossreactivity. effects immunosuppression nab formation tested in
mini-pigs treated immunosuppressant therapy before, a
single aav1/serca2a infusion. aggressive immunosuppression prevent
formation aav1 nabs. conclude immunosuppression unlikely a
viable solution repeat aav1 dosing. strategies reduce nabs heart
failure patients needed increase eligibility gene transfer using aav
vectors.

doi: 10.1038/gt.2015.109 
pmcid: pmc6558655
pmid: 26699914  [indexed medline]

